The Trump administration has withdrawn its proposal to block rebates and discounts given by drug makers to pharmacy benefit managers, Part D plans, and Medicaid managed care organizations.
The Trump administration has withdrawn its proposal to block rebates and discounts given by drug makers to pharmacy benefit managers (PBMs), Part D plans, and Medicaid managed care organizations.
The rule would have excluded rebates from safe harbor protections that currently shelter drug makers’ rebates from penalties under the federal Anti-Kickback Statute and would have formed new safe harbor protections for discounts offered directly to patients, as well as fixed-fee service arrangements between drug makers and PBMs.
HHS previously said that the rule would counteract incentives behind higher list prices; currently, when a list price rises, patients who pay a percentage or all of the list price for a drug see their out-of-pocket expenses increase while PBMs reap financial rewards.
According to a report by Politico, the administration has now decided to withdraw the proposed rule, first put forward in February 2019 and championed by HHS Secretary Alex Azar, who has called the use of rebates in the United States “an absolutely silly system.” The rule reportedly faced dissent from domestic policy chief Joe Grogan and others who believed that it would be too costly to implement.
It had been expected that the rule would shake up the marketplace for biosimilars; while just 7 biosimilars have entered the US market, they have seen low levels of uptake. In at least 1 of those cases, rebates have been blamed for sluggish adoption. In 2017, Pfizer, maker of a biosimilar infliximab product (Inflectra), filed suit against Johnson & Johnson (J&J), maker of the reference infliximab (Remicade), for using the so-called “rebate trap” to block biosimilar competition for its high-selling product.
According to Pfizer’s suit, J&J threatened to withhold rebates (which often grow larger as performance metrics such as market share or volume rise, or which may be bundled together with rebates for other products) from insurers unless they agreed to exclude biosimilars from their formularies.
The now-withdrawn rule could have undercut the incentive for PBMs to favor drugs with higher rebates over drugs, like biosimilars, that have lower costs, and proponents say that it could have allowed for increased biosimilar uptake if drug makers made the decision to compete on price.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.